Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bruker Corp | 58 |
| 2 | Thermo Fisher Scientific Inc | 54 |
| 3 | Gilead Sciences Inc | 46 |
| 4 | Cerus Corp | 36 |
| 5 | Boston Scientific Corp | 34 |
| 6 | Pfizer Inc | 27 |
| 7 | LGC Science Corp SARL | 18 |
| 8 | GSK PLC | 13 |
| 9 | New York University | 12 |
| 10 | State University System of Florida | 11 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 483 |
| 2 | A61P | Therapeutic activity (drug indications) | 471 |
| 3 | C07D | Heterocyclic compounds | 318 |
| 4 | C12Q | Measuring/testing involving enzymes | 287 |
| 5 | C12N | Microorganisms, enzymes | 139 |
| 6 | Y02A | Climate change adaptation | 120 |
| 7 | C07H | Sugars and derivatives | 108 |
| 8 | G01N | Investigating / analysing materials | 98 |
| 9 | C07K | Peptides | 77 |
| 10 | C07C | Acyclic and carbocyclic compounds | 71 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Oligonucleotide conjugates | 1995 | 1,032 | |
| Covalently linked oligonucleotide minor grove binder conjugates | 1998 | Bruker Corp | 332 |
| Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | 2001 | Bruker Corp | 193 |
| Covalently linked oligonucleotide minor grove binder conjugates | 2000 | 161 | |
| Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | 2002 | 134 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 19 |
| 2017 | 17 |
| 2018 | 16 |
| 2019 | 18 |
| 2020 | 26 |
| 2021 | 9 |
| 2022 | 14 |
| 2023 | 9 |
| 2024 | 9 |
| 2025 | 4 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Ikuo Igarashi | Obihiro University of Agriculture and Veterinary Medicine | 13 |
| 2 | Mohamed Abdo Rizk | Obihiro University of Agriculture and Veterinary Medicine | 11 |
| 3 | Stephen Neidle | Institute of Cancer Research | 10 |
| 4 | Mohammed Mamman | International Centre of Insect Physiology and Ecology | 6 |
| 5 | Harry P. de Koning | University of Glasgow | 5 |
| 6 | Harrison Chitambo | Osaka Prefecture University | 5 |
| 7 | Getachew Terefe | Addis Ababa University | 5 |
| 8 | Andrew S. Peregrine | International Centre of Insect Physiology and Ecology | 5 |
| 9 | S.K. Moloo | International Centre of Insect Physiology and Ecology | 5 |
| 10 | Shiby Kuriakose | University of Manitoba | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Defining the drug incorporation properties of PLA–PEG nanoparticles | 2000 | 222 | Nanoparticle-Based Drug Delivery |
| Trypanosomiasis by Trypanosoma vivax in cattle in the Brazilian semiarid: Description of an outbreak and lesions in the nervous system | 2006 | 202 | Trypanosoma species research and implications |
| Pharmacology of diminazene: a review | 1993 | 193 | Trypanosoma species research and implications |
| Diminazene Attenuates Pulmonary Hypertension and Improves Angiogenic Progenitor Cell Functions in Experimental Models | 2013 | 175 | Pulmonary Hypertension Research and Treatments |
| Lipid-Drug-Conjugate (LDC) Nanoparticles as Novel Carrier System for the Hydrophilic Antitrypanosomal Drug Diminazenediaceturate | 2002 | 174 | Lipid Membrane Structure and Behavior |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition and weight of Berenil?
Which organizations hold the most patents related to Berenil?
What are the main research topics associated with Berenil publications?
Who are the leading authors publishing research on Berenil?
How has patent activity for Berenil changed over recent years?